Müller C, Zhernosekov K, Köster U, Johnston K, Dorrer H, Hohn A, et al. A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α- and β–-Radionuclide Therapy: an in vivo proof-of-Concept Study with a new receptor-targeted Folate Derivative. J Nucl Med. 2012;53:1951.

Article  PubMed  Google Scholar 

Van Laere C, Koole M, Deroose CM, de Voorde MV, Baete K, Cocolios TE, et al. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside. Theranostics. 2024;14:1720–43.

Article  PubMed  PubMed Central  Google Scholar 

Naskar N, Lahiri S. Theranostic Terbium Radioisotopes: challenges in production for clinical application. Front Med. 2021;8:675014.

Article  Google Scholar 

Collins SM, Robinson AP, Ivanov P, Köster U, Cocolios TE, Russell B, et al. Half-life determination of 155 tb from mass-separated samples produced at CERN-MEDICIS. Appl Radiat Isot. 2022;190:110480.

Article  CAS  PubMed  Google Scholar 

Collins SM, Gilligan C, Pierson B, Ramirez N, Goodwin M, Pearce AK, et al. Determination of the 161Tb half-life. Appl Radiat Isot. 2022;182:110140.

Article  CAS  PubMed  Google Scholar 

Müller C, Bunka M, Haller S, Köster U, Groehn V, Bernhardt P, et al. Promising prospects for 44Sc-/47Sc-Based theragnostics: application of 47Sc for Radionuclide Tumor Therapy in mice. J Nucl Med. 2014;55:1658–64.

Article  PubMed  Google Scholar 

Domnanich KA, Eichler R, Müller C, Jordi S, Yakusheva V, Braccini S, et al. Production and separation of 43Sc for radiopharmaceutical purposes. EJNMMI Radiopharm Chem. 2017;2:14.

Article  PubMed  PubMed Central  Google Scholar 

Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23:957–80.

Article  CAS  PubMed  Google Scholar 

Rösch F, Herzog H, Qaim SM. The beginning and development of the Theranostic Approach in Nuclear Medicine, as exemplified by the Radionuclide Pair 86Y and 90Y. Pharmaceuticals. 2017;10:56.

Article  PubMed  PubMed Central  Google Scholar 

Silberstein EB. Radioiodine: the Classic Theranostic Agent. Semin Nucl Med. 2012;42:164–70.

Article  PubMed  Google Scholar 

Aluicio-Sarduy E, Hernandez R, Olson AP, Barnhart TE, Cai W, Ellison PA, et al. Production and in vivo PET/CT imaging of the theranostic pair 132/135La. Sci Rep. 2019;9:10658.

Article  PubMed  PubMed Central  Google Scholar 

Crawford JR, Robertson AKH, Yang H, Rodríguez-Rodríguez C, Esquinas PL, Kunz P, et al. Evaluation of 209At as a theranostic isotope for 209At-radiopharmaceutical development using high-energy SPECT. Phys Med Biol. 2018;63:045025.

Article  CAS  PubMed  Google Scholar 

McNeil BL, Robertson AKH, Fu W, Yang H, Hoehr C, Ramogida CF, et al. Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair. EJNMMI Radiopharm Chem. 2021;6:6.

Article  PubMed  PubMed Central  Google Scholar 

Koniar H, Rodríguez-Rodríguez C, Radchenko V, Yang H, Kunz P, Rahmim A, et al. SPECT imaging of 226Ac as a theranostic isotope for 225Ac radiopharmaceutical development. Phys Med Biol. 2022;67:185009.

Article  CAS  Google Scholar 

Koniar H, Wharton L, Ingham A, Rodríguez-Rodríguez C, Kunz P, Radchenko V, et al. In vivo quantitative SPECT imaging of actinium-226: feasibility and proof-of-concept. Phys Med Biol. 2024;69:155003.

Article  Google Scholar 

Türler A. Matched pair theranostics: Medicinal Chemistry and Chemical Biology highlights. Chimia. 2019;73:947.

Article  PubMed  Google Scholar 

Miller C, Rousseau J, Ramogida CF, Celler A, Rahmim A, Uribe CF. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics. 2022;12:232–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nica N. Nuclear Data sheets for a = 155. Nucl Data Sheets. 2019;160:1–404.

Article  CAS  Google Scholar 

Brosch-Lenz J, Yousefirizi F, Zukotynski K, Beauregard J-M, Gaudet V, Saboury B, et al. Role of Artificial Intelligence in Theranostics: toward Routine Personalized Radiopharmaceutical therapies. PET Clin. 2021;16:627–41.

Article  PubMed  Google Scholar 

Wharton L, McNeil SW, Merkens H, Yuan Z, Van de Voorde M, Engudar G, et al. Preclinical evaluation of [155/161Tb]Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours. Molecules. 2023;28:3155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bolcaen J, Gizawy MA, Terry SYA, Paulo A, Cornelissen B, Korde A, et al. Marshalling the potential of Auger Electron Radiopharmaceutical Therapy. J Nucl Med. 2023;64:1344–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehenberger S, Barkhausen C, Cohrs S, Fischer E, Grünberg J, Hohn A, et al. The low-energy β – and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nucl Med Biol. 2011;38:917–24.

Article  CAS  PubMed  Google Scholar 

Reich CW. Nuclear Data sheets for a = 161. Nucl Data Sheets. 2011;112:2497–713.

Article  CAS  Google Scholar 

Müller C, van der Meulen NP, Schibli R. Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics. Eur J Nucl Med Mol Imaging. 2023;50:3181–4.

Article  PubMed  Google Scholar 

Dellepiane G, Casolaro P, Favaretto C, Grundler PV, Mateu I, Scampoli P, et al. Cross section measurement of terbium radioisotopes for an optimized 155Tb production with an 18 MeV medical PET cyclotron. Appl Radiat Isot. 2022;184:110175.

Article  CAS  PubMed  Google Scholar 

Müller C, Fischer E, Behe M, Köster U, Dorrer H, Reber J, et al. Future prospects for SPECT imaging using the radiolanthanide terbium-155 — production and preclinical evaluation in tumor-bearing mice. Nucl Med Biol. 2014;41:e58–65.

Article  PubMed  Google Scholar 

Favaretto C, Talip Z, Borgna F, Grundler PV, Dellepiane G, Sommerhalder A, et al. Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging. EJNMMI Radiopharm Chem. 2021;6:37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1919–30.

Article  PubMed  PubMed Central  Google Scholar 

Borgna F, Barritt P, Grundler PV, Talip Z, Cohrs S, Zeevaart JR, et al. Simultaneous visualization of 161Tb- and 177Lu-Labeled somatostatin analogues using dual-isotope SPECT Imaging. Pharmaceutics. 2021;13:536.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wharton L, McNeil SW, Zhang C, Engudar G, Van de Voorde M, Zeisler J et al. Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH. Nucl Med Biol. 2024;136–7:108925.

Cassells I, Ahenkorah S, Burgoyne AR, Van de Voorde M, Deroose CM, Cardinaels T, et al. Radiolabeling of Human serum albumin with Terbium-161 using mild conditions and evaluation of in vivo Stability. Front Med. 2021;8:675122.

Article  Google Scholar 

McNeil SW, Van de Voorde M, Zhang C, Ooms M, Bénard F, Radchenko V, et al. A simple and automated method for 161Tb purification and ICP-MS analysis of 161Tb. EJNMMI Radiopharm Chem. 2022;7:31.

Article  PubMed  PubMed Central  Google Scholar 

Marin I, Rydèn T, Van Essen M, Svensson J, Gracheva N, Köster U, et al. Establishment of a clinical SPECT/CT protocol for imaging of 161Tb. EJNMMI Phys. 2020;7:45.